©2024 Stanford Medicine
Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension
Not Recruiting
Trial ID: NCT02250651
Purpose
This study will evaluate the efficacy and safety of bimatoprost sustained-release (SR) in patients with open-angle glaucoma or ocular hypertension. The study includes a 12-month treatment period with an 8-month extended follow-up.
Official Title
The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension
Stanford Investigator(s)
Ann Caroline Fisher, MD
Clinical Associate Professor, Ophthalmology
Eligibility
Inclusion Criteria:
- Diagnosis of either open-angle glaucoma or ocular hypertension in each eye and both eyes require IOP-lowering treatment.
Exclusion Criteria:
* Previous enrollment in another Allergan Bimatoprost SR Study
* Eye surgery (including cataract surgery) and/or any eye laser surgery within the past 6 months in the study eye
* Anticipated need for laser eye surgery within the first 52 weeks of the study duration
* History of glaucoma surgery
Intervention(s):
drug: Timolol Vehicle (placebo)
drug: Bimatoprost SR
other: Sham: Applicator Without Needle
drug: Active Comparator: Timolol 0.5%
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Mariana Nunez
650-724-3734